Dabrafenib mesylate

• CAT Number: I006368
• CAS Number: 1195768-06-9 (mesylate)
• Molecular Formula: C24H24F3N5O5S3
• Molecular Weight: 615.66
• Purity: ≥95%
• Synonyms: Dabrafenib mesylate; GSK 2118436B; GSK2118436B; GSK-2118436B; GSK2118436 Methane sulfonate salt; Brand name: Taflinar.;N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate
• Target: B-raf (BRAF) inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid
• InChI: InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
• InChIKey: YKGMKSIHIVVYKY-UHFFFAOYSA-N
• SMILES: CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O

Dabrafenib Mesylate(CAT: I006368) is a potent and selective inhibitor of BRAF kinase, specifically targeting the mutant BRAF V600E. By inhibiting the RAF/MEK/ERK signaling pathway, it reduces tumor cell proliferation and promotes apoptosis, making it effective in treating cancers driven by this mutation, such as melanoma. Dabrafenib Mesylate is used in oncology research to study BRAF mutations, develop targeted therapies, and explore combination treatments with MEK inhibitors. Its oral bioavailability and specificity have made it a cornerstone in advancing precision medicine for cancers associated with MAPK pathway dysregulation.